# 1 A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety,

# 2 Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-

## 3 COV1901(Beta) SARS-CoV-2 Vaccine in Adults

- 4 Chia En Lien<sup>1,2</sup>, Ming-Che Liu<sup>3</sup>, Ning-Chi Wang<sup>4</sup>, Luke Tzu-Chi Liu<sup>1</sup>, Chung□Chin Wu<sup>1</sup>, Wei□Hsuan Tang<sup>1</sup>, Wei-
- 5 Cheng Lian<sup>1</sup>, Kuan-Ying A. Huang<sup>5,6,7</sup>\*, Charles Chen<sup>1,8</sup>\*.

- 7 <sup>1</sup>Medigen Vaccine Biologics Corporation, Taipei, Taiwan
- 8 <sup>2</sup>Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei City, Taiwan
- 9 <sup>3</sup>Clinical Research Centre, Taipei Medical University Hospital Taipei, Taiwan
- 10 <sup>4</sup>Tri-Service General Hospital, Taipei, Taiwan
- <sup>5</sup>Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- 12 <sup>6</sup>Genomics Research Center, Academia Sinica, Taipei, Taiwan.
- 13 <sup>7</sup>Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan,
- 14 Taiwan.
- 15 <sup>8</sup>College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
- 16 \*Co-Corresponding authors:
- 17 Kuan-Ying A. Huang: arthur1726@cgmh.org.tw;
- 18 Charles Chen: charles@medigenvac.com
- 19 Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 vaccine; MVC-COV1901; booster vaccination; SARS-CoV-2 Beta
- 20 variant booster vaccine, Omicron variant
- 21
- 22
- 23

### 24 Abstract

### 25 Background

The use of variant-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as a booster is being evaluated to overcome reduced neutralisation of variants induced by the original SARS-CoV-2 vaccine and waning protection over time.

### 29 Methods

This is a phase one, prospective, randomized, and open-labeled trial to study the safety and 30 31 immunogenicity of a booster dose consisting of a subunit vaccine based on the stabilized prefusion 32 SARS-CoV-2 spike protein, MVC-COV1901 or its Beta version, MVC-COV1901-Beta. Onehundred and seven participants aged  $\geq 18$  and <55 years, who received two or three prior doses of 33 34 MVC-COV1901 vaccines, were enrolled and were to receive a booster dose of either 15 mcg of 35 MVC-COV1901, 15 mcg or 25 mcg of MVC-COV1901-Beta in 1:1:1 ratio. The primary 36 endpoints were the incidences of adverse events and immunogenicity of the booster dose from Visit 2 (the day of the booster) to Visit 5 (four weeks after the booster). Cellular immunity was 37 38 also investigated with memory B cell (MBC) and T cell assays.

### 39 Findings

Adverse reactions after either MVC-COV1901 or MVC-COV1901-Beta booster doses after 40 two or three doses of MVC-COV1901 were comparable and mostly mild and transient. At four 41 weeks after the booster dose, participants with two prior doses of MVC-COV1901 exhibited 42 numerically higher levels of neutralising antibodies against SARS-CoV-2 or Beta variant than 43 participants with three prior doses of MVC-COV1901 regardless of the type of booster used. 44 However, compared to 15 mcg of MVC-COV1901, 25 mcg of MVC-COV1901-Beta significantly 45 46 improved neutralising antibody titre against Beta variant and BA.4/BA.5 Omicron variant 47 pseudoviruses. The booster dose also significantly increased the proportion of spike-specific

48 MBCs, including those of Beta and Omicron variants.

### 49 Interpretation

50 MVC-COV1901-Beta can be effectively used as a booster dose against SARS-CoV-2,
51 including the circulating BA.4/BA.5 Omicron variant.
52 Funding

- 53 Medigen Vaccine Biologics Corporation
- 54

### 55 Introduction

The vaccine efficiency against the SARS-CoV-2 virus is hampered by the circulation of 56 57 variants resistant to antibody neutralisation imparted by the SARS-CoV-2 vaccine based on the ancestral strain [1, 2]. As of August 2022, WHO has updated its SAR-CoV-2 list of variants of 58 59 concern (VoC) to consist solely of the Omicron variant and its subvariants [3]. The implication of 60 the Omicron variants as the circulating VoC is that primary series and even booster vaccination 61 with currently available vaccines have shown to perform poorly against the current circulating 62 Omicron variant and its subvariants in general, including the BA.2 and BA.4/BA.5 subvariants [4, 63 5]. Various Omicron variant-based vaccines have been developed or are in development, including 64 a monovalent mRNA vaccine based on the Omicron variant by Pfizer/BNT is in the midst of a 65 phase 2/3 clinical trial that claimed to have demonstrated effective neutralisation against the BA.1 subvariant and to a lesser extent, the BA.4 and BA.5 subvariants [6]. Recently, citing a strong 66 67 immune response generated against the ancestral virus and the BA.1 Omicron variant, as well as a good immune response against the BA.4 and BA.5 subvariants, the United Kingdom became the 68 69 first country in the world to approve a bivalent COVID-19 booster vaccine for adults (Moderna 70 bivalent mRNA vaccine based on the ancestral SARS-CoV-2 and the Omicron variant) [7].

71 MVC-COV1901 is a subunit COVID-19 vaccine based on the stable prefusion spike protein 72 S-2P of the ancestral SARS-CoV-2 and adjuvanted with CpG 1018 and aluminum hydroxide [8]. We have previously shown that three doses of MVC-COV1901 can improve neutralising antibody 73 74 response against live SARS-CoV-2 and Omicron variant pseudovirus [9]. We first demonstrated the ability of the Beta variant version of S-2P to protect hamsters from the Delta variant challenge 75 and have also shown improved neutralising antibody levels against a broad spectrum of variants, 76 77 including the current Omicron variant [10]. In the current study, two groups of participants who 78 have received either two or three doses of MVC-COV1901 were administered with a booster dose of either original MVC-COV1901 or MVC-COV1901 based on the Beta variant in two different 79 dose levels (MVC-COV1901-Beta). Reacogenicity and immunogenicity against the original 80 81 SARS-COV-2 and beta variant were examined after the booster dose. To investigate the levels of 82 neutralising antibodies against the Omicron subvariants, we have also conducted a pseudovirus 83 neutralisation assay with the Omicron BA.4/BA.5 pseudovirus.

84

### 85 Methods

86 Study design and participants

87 This was a prospective, randomized, open-labeled phase I study to evaluate the safety, 88 tolerability, and immunogenicity of booster dose with MVC-COV1901 or MVC-COV1901-Beta 89 SARS-CoV-2 vaccine in adult participants. Approximately 120 participants were screened and participants who received two or three prior doses of MVC-COV1901 were respectively placed into 90 91 Group A or Group B. Eligible participants were healthy adults aged from 18 (inclusive) to 55 years 92 who have completed two or three doses of MVC-COV1901 vaccination, with 1st and 2nd doses within 12 weeks, 2nd and 3rd doses between 12 to 24 weeks (for Group B only), and with the latest dose at 93 94 least 84 days before randomization, and did not receive any other investigational or approved COVID-

### 95 19 vaccines.

The trial protocol and informed consent form were approved by the Taiwan Food and Drug Administration and the institutional review boards of the Taipei Medical University Hospital (Taipei, Taiwan) and the Tri-Service General Hospital (Taipei, Taiwan). The trial was conducted in compliance with the principles of the Declaration of Helsinki and Good Clinical Practice. Safety data was monitored by an independent data and safety monitoring board (DSMB). This trial was registered at ClinicalTrials.gov: NCT05216601.

102

### **Randomisation and masking**

103 The randomization of each group was stratified based on site to three treatment arms, 15 mcg of 104 MVC-COV1901, or 15 mcg or 25 mcg of MVC-COV1901-Beta in a 1:1:1 ratio. Blinding was not 105 performed as this was an open-labeled study.

106

### 5 **Procedure and outcomes**

The investigative product MVC-COV1901 contained 15 mcg of SARS-CoV-2 S-2P protein adjuvanted with CpG 1018 750 mcg and aluminium hydroxide 375 mcg, while MVC-COV1901-Beta contained either 15 or 25 mcg of SARS-CoV-2 Beta variant S-2P protein adjuvanted with 750 mcg CpG 1018 and 375 mcg aluminium hydroxide. Booster doses were administered as intramuscular injections of 0.5 mL of the vaccine in the deltoid region of the non-dominant arm, identical to the administration of the original MVC-COV1901 vaccine as primary series [9].

113 The primary safety endpoint of this study was the incidence of adverse events within 28 days 114 of the booster administration. The primary immunogenicity endpoint was the levels of neutralising 115 antibody titres at Visit 5 (4 weeks after the booster dose) and anti-spike immunoglobulin G (IgG) 116 antibody titres at Visits 4 (2 weeks after the booster dose) and 5. Safety was assessed by incidences 117 of solicited AEs for up to seven days after each vaccination and unsolicited AEs for up to 28 days 118 after each vaccination. Other AEs, such as serious adverse events (SAEs) and adverse events of

special interest (AESI), were recorded within the study period. Immunogenicity was assessed by neutralising assay with the original (WT) SARS-CoV-2 and Beta variant and IgG titres in terms of geometric mean titre (GMT) and GMT ratio. Pseudovirus neutralising assays with the Omicron variant (BA.4/BA.5 subvariant) pseudovirus were performed with samples from Visits 2 (baseline) and 5.

Neutralising antibody titres against live SARS-CoV-2 virus were performed with original 124 SARS-CoV-2 (hCoV-19/Taiwan/4/2020, GISAID EPI ISL 411927) and Beta variant (B.1.351, 125 126 hCoV 19/Taiwan/1013) [11]. Briefly, two-fold serial dilutions of serum samples were mixed with 127 equal volumes of 100 TCID<sub>50</sub>/50  $\mu$ L of virus and incubated at 37 °C for one hour. After incubation, the mixtures were added to Vero E6 cells and incubated at 37 °C for four to five days. The 128 129 neutralising antibody titre was defined as the reciprocal of the highest dilution capable of 130 neutralising 50% of the infection (NT<sub>50</sub>) calculated using the Reed-Muench method. Anti-SARS-131 CoV-2 spike immunoglobulin (IgG) levels were measured by enzyme-linked immunosorbent assay 132 (ELISA) using custom-made 96-well plates coated with S-2P antigen [10].

133 Pseudotyped lentivirus with spike proteins of Wuhan wildtype or Omicron (BA.4/BA.5, both possess identical spike protein sequences) variant was used in pseudovirus neutralisation assay 134 135 conducted as reported previously [8]. HEK-293-hAce2 cells were inoculated with two-fold serial dilutions of serum samples mixed with equal volumes of pseudovirus. Fifty percent inhibition 136 137 dilution titres ( $ID_{50}$ ) were calculated with uninfected cells as 100% neutralisation and cells 138 transduced with the virus as 0% neutralisation. The mutations for the Omicron variant 139 (BA.4/BA.5) used in the spike sequence for pseudovirus construction were derived from the WHO source: T19I, del24-26, A27S, del69-70, G142D, V213G, G339D, S371F, S373P, S375F, T376A, 140 141 D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, 142 Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K [3].

143 Frozen peripheral blood mononuclear cells were thawed and used to set up the memory B cell (MBC) assay. Peripheral blood mononuclear cell (PBMC) suspension in RPMI 1640-10% 144 (v/v) fecal calf serum was incubated with an equal volume of polyclonal mitogens mixture, 145 pansorbin cells (1/2500)(heat-killed, formalin-fixed Staphylococcus aureus, Sigma-Aldrich, USA), 146 ODN 2006 (5 mcg/mL)(Class B CpG oligonucleotide, InvivoGen, USA), and pokeweed mitogen 147 148 (40 ng/mL)(Lectin from *Phytolacca americana*, Sigma-Aldrich, USA), at 37°C, 5% CO2 incubator for 6 days. After incubation, cultured PBMCs were harvested, washed and resuspended in RPMI 149 150 1640-10% (v/v) fecal calf serum for following enzyme-linked immunospot assay.

For the enzyme-linked immunospot (ELISpot) assay, 96-well PVDF membrane, 96-well 151 multiscreen filter plate (Millipore, USA) was coated with SARS-CoV-2 spike-2P wild type, 152 153 SARS-CoV-2 spike-2P Beta variant or SARS-CoV-2 spike-2P Omicron variant, at 4°C, overnight. 154 The wells coated with PBS were negative controls and those coated with goat anti-human Ig 155 antibody (Sigma-Aldrich, USA) were used to detect all IgG, IgM and IgA-secreting B cells. The coated plate was washed with PBS and blocked with RPMI 1640-10% (v/v) fecal calf serum at 156 37°C for 2 hours. After washing, cultured PBMC suspension was added to wells (200,000 cultured 157 PBMCs for spike- or PBS-coated well and 5,000 cultured PBMCs for anti-human Ig-coated well) 158 and incubated at 37°C, 5% CO2 incubator for 16 to 18 hours. After washing, the plate was 159 incubated with goat anti-human IgG, IgM or IgA conjugated with alkaline phosphatase 160 161 (Calbiochem, USA) at 37°C for 1 hour. After washing, the plate was developed with an alkaline phosphatase conjugate substrate kit (Bio-Rad, USA) at room temperature. Spot-forming cells were 162 detected and measured with an automatic ELISpot reader. 163

T cell cytokine assay was performed as described previously using ELISpot assays specific for IFN-g and IL-4 [12]. Thawed and rested PBMCs were dispensed at 1 x 10<sup>5</sup> cells per well for IFN-g ELISpot assay (Human IFN-g ELISpot Kit, MABTECH) or 2 x 10<sup>5</sup> cells per well for IL- 4 ELISpot assay (Human IL-4 ELISpot Kit, MABTECH). Cells were stimulated with a pool of

peptides derived from ancestral Wuhan strain (PepTivator SARS-CoV-2 Prot\_S WT Reference Pool, Miltenyi Biotech, Germany) and Beta variant SARS-CoV-2 (PepTivator SARS-CoV-2 Prot\_S B.1.351 Mutation Pool, Miltenyi Biotech, Germany) and incubated at 37 °C for 24 to 48 h. CD3-2 monoclonal antibody were used as the positive control for stimulation. Spots were counted using the CTL automatic ELISpot reader S6 Macro Analyzer (ImmunoSpot, USA). Results were expressed as spot forming units (SFU) per million PBMC.

#### 174 Statistical analysis

As this was an exploratory phase 1 clinical study, the sample size was arbitrarily determined 175 and was not derived from a statistical estimation method and a statistical hypothesis was not used 176 for sample size calculation in this study. All results are presented using descriptive statistics. GMT, 177 178 GMT ratio and corresponding CI are calculated using an ANCOVA model with baseline log-titres, 179 BMI (<30 or >=30 kg/m2) and comorbidity (yes or no) and sex (male or female) as a covariate. 180 GMT ratio is defined as the geometric mean of fold increase of post-study intervention titres over 181 the baseline titres. Prism 6.01 (GraphPad) was used for statistical analysis. Kruskal-Wallis with 182 corrected Dunn's multiple comparisons test was used for comparison of means of the non-183 parametric dataset (Figures 3 and 5), while the Mann-Whitney test was used to compare MBC 184 frequencies at two-time points in Figures 5B and C. Linear regression was used to model the relationship between neutralization titre and IgG MBC frequency in Figure 5D 185

The following groups were used for the study analysis: Safety Set included all randomized participants who received the study intervention; the Full analysis set (FAS) included all randomized participants who received the study intervention, irrespective of their protocol adherence and continued participation in the study. Pre protocol set (PPS) included all participants in the FAS who receive the planned dose of randomized study intervention, and up until Visit 5, did not have laboratory-confirmed COVID-19 infection, were negative for SARS-CoV-2 anti-N tests,

and did not have major protocol deviation that was judged to impact the critical immunogenicitydata.

194

### 195 **Results**

Between May and July 2022, a total of 129 adult participants were screened and 107 eligible 196 197 participants were split into groups of 45 and 62 for Groups A and B, respectively (Figure 1). In terms of the demographics of the participants, all groups had similar mean age and BMI levels, 198 199 although the gender ratios were less equal among the groups (Table 1). The mean intervals 200 between the last dose of MVC-COV1901 and the booster dose were longer in Group A (223.3 to 201 294.5 days) than in Group B (120.9 to 128.0 days). Solicited adverse events (SAEs) are 202 summarized in Figure 2 and tabulated in Tables S1 and S2. Unsolicited AEs are summarized in 203 Table S3. No SAE (grade 3 AEs or higher) or AESI related to the vaccine have been reported after 204 the booster dose. The most common solicited local and systemic effects after any booster dose 205 were pain/tenderness (60.0~73.3% in Group A and 57.1~70.0% in Group B) and malaise/fatigue 206 (33.3~53.3% in Group A and 28.6~40.0% in Group B), respectively. While erythema/redness (two 207 participants in Group A) and fever (two participants in Group A and one participant in Group B) 208 were the least common AEs. The safety profile and incidences of AEs were comparable in both 209 groups (Figure 2, Tables S1-S3).

At V5, Group A participants had numerically higher levels of neutralising antibodies against the ancestral SARS-CoV-2 (WT), with the GMTs ranging from 1352.0 to 3602.8 for Group A compared to 867.9 to 1125.0 for Group B; however, the differences were not significant between the groups (Figure 3A and Table S4). Similar results were observed for the Beta variant, with the neutralizing antibody GMTs for Group A ranging from 225.6 to 1476.9 compared to 147.1 to 459.2 in Group B. In Group A, 25 mcg of MVC-COV1901-Beta significantly (p < 0.05) increased

216	the level of neutralizing antibody against the Beta variant (1476.9 [95% CI 806.4 - 2704.8])
217	compared to 15 mcg of MVC-COV1901 (225.59 [128.1 – 397.2]) (Figure 3A and Table S4).
218	However, in Group B, 15 mcg of MVC-COV1901-Beta induced the highest level of neutralizing
219	antibody against the Beta variant (459.2 [95% CI 322.2 - 654.6]) compared to 15 mcg of MVC-
220	COV1901 (147.1 [102.3 - 211.6) and 25 mcg of MVC-COV1901-Beta (323.8 [227.7 - 460.4])
221	(Figure 3A and Table S4). All participants had high levels of anti-spike IgG at Visits 4 and 5,
222	regardless of the type of booster received or the number of prior doses of MVC-COV1901 (Figure
223	3B). When calculating the GMT ratio of neutralising antibody and IgG titres at V5 or V4 against
224	the baseline (V2) titres, Group B had a minimal increase in GMT ratio compared to Group A
225	(Figure 3C and Table S4). The increase of GMT ratio against the Beta variant was most noticeable
226	in the 25 mcg MVC-COV1901-Beta dosage group for Group A, with V5/V2 neutralising antibody
227	GMT ratio of 202.9 [110.8 – 371.5] and V5/V2 IgG GMT ratio of 49.4 [30.9 – 79.1] in the 25 mcg
228	MVC-COV1901-Beta dosage group compared to for V5/V2 neutralising antibody GMT ratio of
229	31.0 [17.6 – 54.6] and V5/V2 IgG GMT ratio of 20.2 [13.1 – 31.1] in the 15 mcg MVC-COV1901
230	dosage group (Figure 3C and Table S4).

The immunogenicity of booster dose against the Omicron variant was investigated with the BA.4/BA.5 pseudovirus neutralization assay. In both groups at V4, all types of booster doses had uniformly high levels of neutralising antibodies against the WT pseudovirus (Figure 4). Against the BA.4/BA.5 pseudovirus, 25 mcg of MVC-COV1901-Beta elicited a significantly higher (p < 0.01) level of neutralising antibody (ID<sub>50</sub> 425.7 [272.8 – 664.2]) than 15 mcg of MVC-COV1901 (ID<sub>50</sub> 139.1 [76.2 – 254.1]) (Figure 4, Table S4). In Group B, this was not observed and instead, all types of booster doses resulted in similar levels of neutralising antibodies.

Prior to the booster dose at V2, 15 of 18 (83%) Group A subjects had detectable SARSCoV-2 spike-specific IgG memory B cells (MBCs), in which WT, Beta, or Omicron BA.1 spikespecific IgG cells accounted for around 0.5 to 0.6% of total IgG cells in the peripheral blood

(Figure 5A, B; Figure S1). A total of 17 of 18 (94%) Group B subjects had detectable spikespecific IgG MBCs (Figure 5B; Figure S1). Group B subjects had significantly higher pre-existing wild type, Beta and Omicron BA.1 spike-specific IgG MBC frequencies compared to those of group A subjects (wild type,  $0.6\pm0.1$  v.s.  $1.4\pm0.2$ , p = 0.002; Beta,  $0.6\pm0.1$  v.s.  $1.3\pm0.2$ , p = 0.005; Omicron,  $0.5\pm0.1$  v.s.  $0.9\pm0.1$ , p = 0.029, Mann-Whitney test). Pre-existing spike-specific IgM and IgA MBCs were detected in both groups as well, but there is no significant difference in the frequency between the two groups (Fig. 5B).

248 After the booster dose, a significant increase in spike-specific MBC frequency was observed 249 in both Group A and B subjects, of which IgG MBC response dominated (Figure 5B), followed by IgM or IgA MBC responses, indicating the elicitation of immune memory to SARS-CoV-2 spike. 250 251 At two weeks after the booster dose (V4), the WT, Beta, and Omicron BA.1 spike-specific IgG 252 MBC frequency averaged 6.1 $\pm$ 1.3, 6.0 $\pm$ 1.2, and 4.8 $\pm$ 1.3 of total IgG cells (P < 0.0001 for all 253 comparisons between pre-existing and elicited responses), respectively, in Group A (Figure 5B). 254 Enhanced spike-specific IgG MBC responses imparted by the booster were also observed in 255 Group B at day 14 (Figure 5B). Although Group B subjects produced a relatively lower V4 wild 256 type, Beta or Omicron BA.1 spike-specific IgG MBC frequency compared to that of Group A, the 257 difference was not statistically significant.

All treatment groups in Group A elicited a significantly higher WT, Beta or Omicron BA.1 spike-specific IgG MBC frequency than that at the baseline (Figure 5C). Those with Beta 15 mcg booster produced a relatively higher wild type, Beta or Omicron BA.1 spike-specific IgG MBC frequency at V4 than those with wild type or Beta 25 mcg booster, but the difference was not statistically significant (Figure S2).

Within Group B, those with the original MVC-COV1901 booster produced an elevated spike-specific IgG MBC frequency at V4, but did not result in significant increases in Beta or

Omicron BA.1 spike-specific MBC frequency (Figure 5C). Those with Beta 15 mcg booster produced a significantly higher Beta spike-specific IgG MBC response at V4 and those with Beta 25 mcg booster produced significantly higher wild type, Beta and Omicron BA.1 spike-specific IgG MBC frequencies at V4 that those at the baseline (Figure 5C). Nevertheless, similar WT, Beta or Omicron BA.1 spike-specific IgG MBC frequencies were detected among three subgroups at V4 (Figure S2).

271 Significant correlations between spike-specific MBC frequency and serological 272 neutralisation titre were observed for Group A and B subjects, indicating a potential role of spike-273 specific B cell response in the development of antibody immunity upon SARS-CoV-2 274 immunization (Figure 5D; Figure S3).

T cell immune response was investigated by the production of interferon-gamma (IFN-γ)
and IL-4 for Th-1 and Th-2 responses, respectively. Results indicated a generally Th-1-biased T
cell response based on a higher amount of IFN-g induction than IL-4 induction, particularly in
Group A (Figure S4).

279

### 280 Discussion

This was the first clinical trial to investigate the safety and immunogenicity of a Beta variant version of the CpG 1018-adjuvanted subunit SARS-CoV-2 vaccine, MVC-COV1901-Beta, for its use as a heterologous booster dose following two or three doses of MVC-COV1901. The safety profile of MVC-COV1901-Beta was in line with that of the original MVC-COV1901, with pain/tenderness and malaise/fatigue as the most common adverse events while incidences of fever were rarely reported (Figure 2) [9, 11].

In this study, boosting with MVC-COV1901-Beta with 25 mcg of Beta S-2P protein has shown to significantly increase the neutralising antibody titre against the Beta variant as well as

289 the Omicron variant pseudovirus compared to boosting with 15 mcg of MVC-COV1901 290 following two doses of MVC-COV1901 (Figures 3 and 4). The finding is consistent with our previous study, though, with the prototype antigen, which showed the increase of cross-291 292 reactivities against VoCs when antigen amount increases while adjuvant remained unchanged [13]. However, the levels of increase in neutralising antibody titre were lower in participants who 293 294 had received three doses of MVC-COV1901 prior to boosting (Group B) (Figures 3 and 4). We 295 attribute this to the differences in intervals between the last dose of MVC-COV1901 to the booster dose, which in Group A ranged from a mean of 223.3 to 294.5 days, while ranged from a 296 297 mean of 109.2 to 128 days for Group B (Table 1). As less time has passed in Group B following 298 the last vaccination compared to Group A, the baseline titres for Group B were higher and the 299 boosting effect was less dramatic than that of Group A. In addition, in the results from our 300 previous study in the course of three doses of MVC-COV1901 vaccination, the rate of 301 neutralising antibody titre decay was slower after the third (booster) dose compared to the second dose, which could also explain the higher baseline titres in Group B [9]. 302

Studies before the emergence of the Omicron variant demonstrated a correlation between 303 the neutralizing antibody levels and the protection from infection [14]. However, the correlation 304 between the neutralizing antibody level and the protection from the Omicron variant infection is 305 yet to be determined. The vastly decreased protection against infection due to the vaccine escape 306 307 strain reported from vaccine effectiveness studies indicates that none of the homologous 308 regimens based on the prototype vaccine could be an optimal and durable tool to control the 309 transmission and infection [1]. The revised target product profile for the COVID-19 vaccine 310 published by WHO in April 2022 reflected the paradigm shift and emphasized the role of a 311 booster vaccine for protection against severe outcomes, including hospitalization, and long 312 COVID [15]. T-cell immune response against SARS-CoV-2 is known to play a crucial role in improving the breadth of coverage against VoCs, and offering protection against severe 313

outcomes [16]. In patients with immune-mediated inflammatory diseases on B cell depleting therapies breakthrough infections were frequent and associated with severe outcomes [17]. These findings indicate that to achieve the revised target product profile of the COVID vaccine under the era of the Omicron variant, the roles of T and B cell immune responses should be looked at as a whole.

319 This is the first study to report Omicron-specific memory B cell activities after a Beta 320 variant version of the CpG 1018-adjuvanted subunit vaccine SARS-CoV-2 vaccine. The cellular 321 immunity after the booster dose was shown by the proliferation and expansion of spike-specific 322 MBCs, indicating immune memory recall induced by the booster dose (Figure 5). Regardless of 323 the type of booster used, higher proportions of MBC with IgGs specific to WT, Beta, or Omicron 324 spikes were seen after the booster dose, thus MBCs recalled by the booster dose are cross-325 reactive against all strains tested (Figures 5B and C). The dominance of IgG MBC expansion 326 also reflects the involvement of germinal center reaction and the establishment of spike-specific 327 B cell pools, similar to the findings after the mRNA-1273 boost [18]. The potency and epitope 328 recognition of spike-specific B cell repertoire elicited by subunit vaccine boost, especially those cross-reacting with the Omicron variant, require further investigation. 329

330 While homologous booster after two doses of vaccination provided higher protection 331 against hospitalization against the Omicron variant, the vaccine efficiencies against infection still 332 remained poor [19, 20]. To better counter the circulating variants, updated version of vaccines, 333 including MVC-COV1901-Beta, have been developed and is in the progress of the deployment. 334 The recently approved bivalent mRNA-1273.214 based on the ancestral and Omicron strains 335 imparted a 5.4-fold increase in neutralising antibody response against the BA.4/BA.5 subvariants 336 in a phase 2/3 clinical trial in participants with three prior doses of mRNA-1273 [21]. 337 Pfizer/BioNTech have developed Omicron-adapted monovalent and bivalent versions of the 338 vaccine which elicited a 13.5 to 19.6-fold increase and 9.1 to 10.9-fold increase, respectively, in

339	neutralizing antibody titers against the Omicron BA.1 variant in a phase 2/3 trial given as a
340	fourth dose [6]. Another monovalent adjuvanted subunit vaccine by Sanofi/GSK also generated
341	higher titres of neutralising antibody against the Omicron BA.1 variant compared to other
342	vaccines tested when used as a third dose booster [22].

One of the limitations of this study includes, as stated above, the differences in the time interval between the last and booster dose in Groups A and B, thus the two groups could not be compared directly. In cellular immunity assay, we did not perform surface staining and subpopulation gating and thus we could not distinguish between single-variant from dual/multivariant spike-specific MBCs, as has been shown for mRNA-1273 [23]. The sample size was not sufficient to compare all the endpoints across treatment arms, particularly, the efficacy.

In this interim report, we found that heterologous booster with the Beta variant construct vaccine can generate a broad immune response that cross-react with the Omicron variant. The finding support further clinical development of this Beta variant version vaccine.

352

### 353 Conflict of Interest Disclosure:

- 354 C. E. L., L. T.-C.- L., C.-C. W., W.-H. T., W.-C. L., and C. C. are employees of Medigen Vaccine
- Biologics Corporation. M.-C. L., N.-C. W., and K.-Y. A. H. declared no conflict of interest.

356 All authors have reviewed and agreed to the final version of the manuscript.

357

### 358 Funding/Support:

- 359 Medigen Vaccine Biologics Corporation.
- **360 Role of the Funder/Sponsor:**

361 Medigen Vaccine Biologics (the study sponsor) had a role in study design, data analysis,

362 anddata interpretation, but had no role in data collection, or writing of the clinical report.

### **363** Author Contributions:

- Concept, design, and leading the clinical trial: C. E. L. and C. C.
- 365 Acquisition and interpretation of data: M.-C. L., N.-C. W., and K.-Y. A. H.
- 366 Data analysis and Drafting of the manuscript: C. E. L., L. T.-C. L., and C. C.
- 367 Vaccine production: C.-C. W., W.-H. T., and W.-C. L.

### 368 Data availability

369 Data sharing is not applicable to this study, as it is an interim analysis of an ongoing clinical 370 trial.

#### 371 Acknowledgements

We thank the Institute of Biomedical Sciences of Academia Sinica for performing the livevirus and pseudovirus neutralization assay.

### 374

#### 375 **References**

- Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, *et al.* Covid-19 vaccine
   effectiveness against the Omicron (B. 1.1. 529) variant. New England Journal of Medicine.
   2022 Apr 21;386(16):1532-46.
- Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, *et al.* Omicron escapes the majority of
   existing SARS-CoV-2 neutralizing antibodies. Nature. 2022 Feb;602(7898):657-63.
- World Health Organization. Tracking SARS-CoV-2 variants. Who.int. 2022. Available from:
   https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ [Accessed 25 August 2022].
- Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, *et al.* Rapid decline in vaccine-boosted
   neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Reports Medicine. 2022 Jul
   19;3(7):100679.
- Qu P, Faraone J, Evans JP, Zou X, Zheng YM, Carlin C, *et al.* Neutralization of the SARS CoV-2 omicron BA. 4/5 and BA. 2.12. 1 subvariants. New England Journal of Medicine. 2022

388 Jun 30;386(26):2526-8.

414

- 389 6. Pfizer. Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates
- Demonstrate High Immune Response Against Omicron. Pfizer.com. 2022. Available from:
- 391 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-

392 omicron-adapted-covid-19 [Accessed 25 August 2022].

- Medicines and Healthcare products Regulatory Agency, Government of the United Kingdom.
   First bivalent COVID-19 booster vaccine approved by UK medicines regulator. Gov.uk. 2022.
   Available from: https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine approved-by-uk-medicines-regulator [Accessed 25 August 2022].
- 8. Kuo TY, Lin MY, Coffman RL, Campbell JD, Traquina P, Lin YJ, *et al.* Development of CpG-
- adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVIDScientific reports. 2020 Nov 18;10(1):1-0.
- 9. Hsieh SM, Chang SC, Cheng HY, Shih SR, Lien CE. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study. Infectious Diseases and Therapy. 2022 May 17:1-2.
- 404 10. Kuo TY, Lien CE, Lin YJ, Lin MY, Wu CC, Tang WH, et al. Protection of Hamsters
  405 Challenged with SARS-CoV-2 Delta Variant after Two Doses of Adjuvanted SARS-CoV-2
  406 Stabilized Prefusion Spike Protein (S-2P) and a Single Dose of Beta Variant S-2P. The Journal
  407 of infectious diseases. 2022 Apr 22.
- 11. Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, *et al.* Safety and
  immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein
  vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebocontrolled phase 2 trial in Taiwan. The Lancet Respiratory Medicine. 2021 Dec 1;9(12):1396406.
- 12. Hsieh SM, Liu WD, Huang YS, Lin YJ, Hsieh EF, Lian WC, *et al.* Safety and immunogenicity

of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901)

- Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, doseescalation study. EClinicalMedicine. 2021 Aug 1;38:100989.
- Lien CE, Kuo TY, Lin YJ, Lian WC, Lin MY, Liu LT, *et al.* Evaluating the neutralizing ability
  of a CpG-adjuvanted S-2P subunit vaccine against severe acute respiratory syndrome
  coronavirus 2 (SARS-CoV-2) variants of concern. Clinical Infectious Diseases. 2022 Jun
  1;74(11):1899-905.
- 421 14. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing

- 422 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
- 423 infection. Nature medicine. 2021 Jul;27(7):1205-11.
- 424 15. World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines. Revised
- 425 version April 2022. Who.int. 2022. Available from:
- 426 https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines
- 427 [Accessed 28 August 2022].
- 428 16. Moss P. The T cell immune response against SARS-CoV-2. Nature immunology. 2022
  429 Feb;23(2):186-93.
- 430 17. Calabrese CM, Husni EM, Moss BM, Fernandez AJ, Jin Y, Kirchner E, Calabrese LH.
  431 Breakthrough SARS-CoV-2 infections in immune mediated disease patients undergoing B cell
  432 depleting therapy. medRxiv. 2022.02.21.22271289
- 18. Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, *et al.* Increased memory B
  cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022 Jul;607(7917):128134.
- 436 19. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, *et al.* Effectiveness of mRNA-1273
  437 against SARS-CoV-2 Omicron and Delta variants. Nature Medicine. 2022 May;28(5):1063-71.
- 20. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, *et al.* Effectiveness of
  a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A
  retrospective cohort study. The Lancet Regional Health-Americas. 2022 May 1;9:100198.
- 21. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, *et al.* A Bivalent Omicroncontaining Booster Vaccine Against Covid-19. medRxiv. 2022.06.24.22276703
- 22. Launay O, Cachanado M, Ngũyen LB, Ninove L, Lachâtre M, Ghezala IB, *et al.*Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine. New England
  Journal of Medicine. 2022 July 28:387:374-376.
- Gagne M, Moliva JI, Foulds KE, Andrew SF, Flynn BJ, Werner AP, *et al.* mRNA-1273 or
  mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing
  responses, and protection from Omicron. Cell. 2022 Apr 28;185(9):1556-71.
- 449
- 450

### 452 Figures





455





457 Figure 2. Solicited local and systemic adverse events for each of the treatment groups in Groups A

458 and B



461 Figure 3. Immunogenicity of the booster dose. A) neutralising antibody titre against live ancestral
462 (WT) SARS-CoV-2 and Beta variant; B) anti-SARS-CoV-2 spike IgG antibody titre; C) GMT ratio

of neutralising antibody titres of V5/V2 (left) and anti-spike IgG titres at V4/V2 and V5/V2 (right). For (**A**) and (**B**), results are expressed as symbols representing GMT and error bars represent 95% confidence intervals. For (**C**), results are expressed as mean GMT ratio with error bars representing 95% confidence intervals. Statistical significance was calculated using the Kruskal-Wallis test with corrected Dunn's multiple comparisons test. \* = p < 0.05, \*\* = p < 0.01, \*\*\* = p < 0.001, \*\*\*\* = p < 0.0001

469



Figure 4. Pseudovirus neutralisation assay of pseudovirus with spike proteins of the original SARS-CoV-2 or Omicron variant (BA.4/BA.5) with serum samples from Visits 2 (baseline) and 5 (2 weeks after the booster dose). Blue and red symbols show individual titre values, while bars represent GMTs and error bars represent 95% confidence intervals. Fold differences between GMT's are shown numerically above the upper dotted line. Dotted lines indicate the starting dilution (20; lower

- dotted line) and the final dilution (2560; upper dotted line) for the assay, and all values below 20 are
- 477 tabulated as 10. Statistical significance was calculated using the Kruskal-Wallis test with corrected
- 478 Dunn's multiple comparisons test. \* = p < 0.05, \*\* = p < 0.01, \*\*\* = p < 0.001, \*\*\*\* = p < 0.001

479



482 Figure 5. SARS-CoV-2 spike-specific memory B cell (MBC) response before and after the booster 483 dose. (A) Illustration of SARS-CoV-2 spike-specific MBC frequency, measured by ELISpot. In the ELISpot assay, antigen-coated wells were used to assess antigen-specific MBC, PBS-coated wells 484 485 were used as negative controls, anti-Ig coated wells were used to assess total IgG MBC. The 486 numbers (in italics) of spots and cultured cells incubated in the ELISpot assay were shown below 487 each image. Each spot represents an antibody-secreting cell. The frequency of antigen-specific IgG 488 MBC was calculated as the percentage of total IgG MBC. Subject 02-023 is an adult who had two 489 prior doses of MVC-COV1901 and received a booster dose of MVC-COV1901 containing a Beta 490 variant spike of 15 mcg. V2, the vaccination day; V4, 14 days after the booster dose. (B) spike-491 specific MBC frequency in the peripheral blood was measured in those with two (group A) and three 492 (group B) initial doses of MVC-COV1901, before (V2) and 14 days (V4) after the booster dose, 493 with memory B cell ELISpot assay. Wild type (WT), Beta, and Omicron BA.1 spike-specific IgG, 494 IgM or IgA MBC frequencies were shown in mean  $\pm$  SEM in the figure. Each symbol represents a 495 sample (subject). (C) spike-specific MBC frequency in the subgroups, i.e., booster dose with MVC-496 COV1901 containing Wuhan wild type spike, booster dose with MVC-COV1901 containing Beta variant spike 15 mcg, and booster dose with MVC-COV1901 containing Beta variant spike 25 mcg, 497 498 of group A and B. Wild type (WT), Beta, and Omicron BA.1 spike-specific IgG, IgM or IgA MBC 499 frequencies were shown in mean  $\pm$  SEM in the figure. Each symbol represents a sample (subject). 500 (D) Relationship of spike-specific IgG MBC frequency and serological neutralisation titre with wild 501 type and Omicron variant BA.4/BA.5 SARS-CoV-2 pseudovirus among group A and B subjects. 502 Linear regression was used to model the relationship between two variables. pNT, pseudovirus 503 neutralisation titre. Mann-Whitney test was used to compare MBC frequencies at two-time points. 504 \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001. ns, not significant.

505

### 507 Tables

508

### **Table 1.** Demographics and baseline characteristics of the participants for Group A and Group B.

	Group A (N=45)		
	MVC-COV1901 (15 mcg)	MVC-COV1901 (15 mcg, beta)	MVC-COV1901 (25 mcg, beta)
n	15	15	15
age mean (SD)	36.9 (9.25)	34.7 (7.71)	39.5 (9.16)
Male	53.3%	73.3%	60.0%
BMI	24.991	24.710	26.215
HIV-positive	0	0	0
HBsAg-positive	0	0	0
Anti-HCV antibody-positive	0	0	0
Cardiovascular disease	0	0	0
Cerebrovascular disease	0	0	0
Malignancy	0	0	0
HbA1c higher than the normal range	0	1 (6.7%)	0
1, 2 dose interval (days) mean (SD)	33.1 (6.55)	34.5 (4.21)	32.6 (4.98)
2, 3 dose interval (days) mean (SD)	-	-	-
Last dose interval (days) mean (SD)	270.6 (101.06)	223.3 (36.98)	294.5 (90.88)
2ast asse meet (aa js) mean (sz)			
	Group B (N=61)		
	Group B (N=61) MVC-COV1901 (15 mcg)	MVC-COV1901 (15 mcg, beta)	MVC-COV1901 (25 mcg, beta)
n	Group B (N=61) MVC-COV1901 (15 mcg) 21	MVC-COV1901 (15 mcg, beta) 21	MVC-COV1901 (25 mcg, beta) 20
n age mean (SD)	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24)	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53)	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98)
n age mean (SD) Male	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1%	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6%	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0%
n age mean (SD) Male BMI	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606
n age mean (SD) Male BMI HIV-positive	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0
n age mean (SD) Male BMI HIV-positive HBsAg-positive	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0 0	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0 0	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0 0
n age mean (SD) Male BMI HIV-positive HBsAg-positive Anti-HCV antibody-positive	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0 0 0	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0 0 0	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0 0 0
n age mean (SD) Male BMI HIV-positive HBsAg-positive Anti-HCV antibody-positive Cardiovascular disease	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0 0 0 0 0	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0 0 0 1 (4.8%)	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0 0 0 0 0
n age mean (SD) Male BMI HIV-positive HBsAg-positive Anti-HCV antibody-positive Cardiovascular disease Cerebrovascular disease	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0 0 0 0 0 0 1 (4.8%)	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0 0 0 1 (4.8%) 0	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0 0 0 0 0 0 0
n age mean (SD) Male BMI HIV-positive HBsAg-positive Anti-HCV antibody-positive Cardiovascular disease Cerebrovascular disease Malignancy	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0 0 0 0 0 0 1 (4.8%) 0	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0 0 0 1 (4.8%) 0 0	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0 0 0 0 0 0 0 0 1 (5.0%)
n age mean (SD) Male BMI HIV-positive HBsAg-positive Anti-HCV antibody-positive Cardiovascular disease Cerebrovascular disease Malignancy HbA1c higher than the normal range	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0 0 0 0 0 0 1 (4.8%) 0 2 (9.5%)	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0 0 0 1 (4.8%) 0 0 0 0	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0 0 0 0 0 0 0 1 (5.0%) 1 (5.0%)
n age mean (SD) Male BMI HIV-positive HBsAg-positive Anti-HCV antibody-positive Cardiovascular disease Cerebrovascular disease Malignancy HbA1c higher than the normal range 1, 2 dose interval (days) mean (SD)	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0 0 0 0 0 1 (4.8%) 0 2 (9.5%) 38.7 (7.80)	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0 0 0 1 (4.8%) 0 0 0 0 37.5 (3.04)	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0 0 0 0 0 0 0 1 (5.0%) 1 (5.0%) 37.6 (2.78)
n age mean (SD) Male BMI HIV-positive HBsAg-positive Anti-HCV antibody-positive Cardiovascular disease Cerebrovascular disease Malignancy HbA1c higher than the normal range 1, 2 dose interval (days) mean (SD) 2, 3 dose interval (days) mean (SD)	Group B (N=61) MVC-COV1901 (15 mcg) 21 36.8 (9.24) 38.1% 24.440 0 0 0 0 0 1 (4.8%) 0 2 (9.5%) 38.7 (7.80) 111.6 (11.82)	MVC-COV1901 (15 mcg, beta) 21 38.6 (7.53) 47.6% 24.210 0 0 0 1 (4.8%) 0 0 0 0 37.5 (3.04) 113.2 (16.44)	MVC-COV1901 (25 mcg, beta) 20 38.0 (8.98) 55.0% 24.606 0 0 0 0 0 0 0 1 (5.0%) 1 (5.0%) 1 (5.0%) 37.6 (2.78) 109.2 (9.41)





□ V2 (Baseline) V5 (4 weeks after booster)







